To address this issue, the most current guidelines released in 2015 recommend that DMD patients start therapy with ACE inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) by 10 years of age or sooner, based on mounting evidence that early stages of cardiac deterioration may have already begun [5,6]. This evidence concerns the gene ACE and Duchenne muscular dystrophy.